FDA Approves First Gene Therapy for Rare Sanfilippo Syndrome
Federal health regulators have granted approval to rebisufligene etisparvovec, marketed as Fayuvi, making it the very first therapeutic option authorized for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), more commonly known as Sanfilippo syndrome type A. The announcement, issued by the U.S. Food and Drug Administration (FDA), marks a major clinical milestone for families dealing with an ultra-rare and ultimately fatal genetic condition.
Understanding Sanfilippo Syndrome Type A
MPS IIIA is an inherited, progressive metabolic disorder that triggers rapid neurodegeneration during early childhood. The underlying cause stems from a critical deficiency in the sulfamidase (SGSH) enzyme. Without enough of this specific enzyme, a complex sugar molecule called heparan sulfate builds up inside the body and brain, progressively damaging the central nervous system.
Children born with MPS IIIA typically experience global developmental delays during their early years. These delays are followed by a steady, heartbreaking loss of cognitive, language, and motor skills. Because of its devastating cognitive toll, the condition is sometimes informally described as a form of childhood dementia. The median life expectancy for affected individuals is approximately 15 years.
How the New Gene Therapy Works
Developed by Ultragenyx Pharmaceutical, rebisufligene etisparvovec is administered as a single intravenous infusion. The treatment utilizes an adeno-associated virus serotype 9 (AAV9) vector to transport a functional copy of the SGSH gene directly into the patient’s cells. Once delivered, this working gene enables the body to produce the missing sulfamidase enzyme, allowing heparan sulfate to be properly broken down and clearing hazardous accumulations throughout the central nervous system.
Dr. Megha Kaushal, acting deputy director of the FDA’s Office of Therapeutic Products, highlighted the clinical significance of the approval. She noted that achieving meaningful neurodevelopmental benefits through a single intravenous dose demonstrates that systemic AAV9-mediated gene delivery can successfully reach the central nervous system at therapeutically relevant levels in young patients.
Clinical Trial Findings and Safety Profile
The FDA based its approval on data gathered from an open-label, single-arm, multicenter clinical trial involving pediatric MPS IIIA patients. The study evaluated mean changes in cognitive scores among children between the ages of 2 and 5 years. According to agency reports, children who received the gene therapy maintained or improved their cognitive function when compared against an untreated historical control cohort.
Potential Risks and Side Effects
While the therapy offers new hope, clinical evaluations revealed several common adverse reactions. The most frequently observed side effects included:
- Elevated liver enzymes
- Nausea and vomiting
- Fever and decreased appetite
- Decreased white blood cell and platelet counts
- Increased amylase levels
Furthermore, safety warnings associated with the treatment highlight the risk of thrombotic microangiopathy. The FDA also noted that, similar to other AAV-based gene therapies, there is a potential long-term risk that the newly inserted genetic material could integrate into the host genome, which carries a theoretical risk of tumor development.
The regulatory approval follows a previous rejection by the FDA a little over a year ago due to manufacturing-related concerns. Following this clearance, the manufacturer has set a U.S. list price of $3.95 million for the one-time intervention.
Source: MedPage Today
